This week Vienna is hosting the largest European Urolithiasis Meeting, organised every two years by the European Association of Urology (EAU). The event will bring together opinion leaders and experts who will present the latest international scientific advances to improve the treatment of this disease. In Europe, urological diseases (lithiasis, infections, hyperactive bladder, painful bladder syndrome, interstitial cystitis, catheter calcification...) are the second most common cause of primary care consultations. H
Highlights in the scientific programme include the Metabolics and stone composition session during which a study will be presented about the association between Body Mass Index (BMI) and urine pH carried out by a specialist metabolic stone clinic in the United Kingdom —a country where Devicare recently announced its entry—. The study is supported by researchers from the Cambridge University Hospitals and the NHS Foundation Trust.
Controlling urine pH has allowed a new approach to be established not only in the treatment, but also in the prevention of lithiasis and other frequently occurring urological diseases. Devicare, in collaboration with the Renal Lithiasis Research Laboratory of the University of the Balearic Islands (UIB), is innovating with first-in-class methods in this field such as Lit-Control.
Currently more than 16,000 professionals form part of the EUA, which includes a specific section for urolithiasis (EULIS). EULIS is presided by Prof. Kemal Sarica (Turkey).
